SAN DIEGO, Feb. 25, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, March 3, 2016 at 5:00 p.m. ET to report its fourth quarter and full year 2015 financial results and provide a corporate update.
In order to participate in the conference call, please dial 1-877-303-6235 (domestic) or 1-631-291-4837 (international) and refer to conference ID 58417776. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell-based product pipeline is comprised of immuno-oncology therapies, including off-the-shelf NK- and T-cell-based candidates derived from engineered induced pluripotent cells, and immuno-regulatory therapies, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner Stern Investor Relations, Inc. 212.362.1200 [email protected]


Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 



